A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer
- PMID: 32596075
- PMCID: PMC7313428
- DOI: 10.7759/cureus.8257
A Retrospective Review of Tumor Lysis Syndrome Associated With Colorectal Cancer
Abstract
Tumor lysis syndrome (TLS) is a life-threatening oncologic condition that is most commonly linked with hematologic malignancies and uncommonly seen in solid tumors, including colorectal cancer (CRC). Therefore, a lack of awareness regarding TLS in CRC could lead to significant morbidity and mortality. This study aims to explore the clinical characteristics and outcomes of TLS in patients with CRC. A systematic review of the literature was performed by searching PubMed using the keywords "tumor lysis syndrome" and "colorectal cancer". The English-language case reports and abstracts that the search results yielded were reviewed, and additional articles of interest were identified from reference lists. Information regarding the patients (age at diagnosis, presentation, and comorbidities), the tumors (histology, grade, and stage), radiologic investigations, treatment modalities (surgery, radiation, and systemic therapy), and the outcomes (response, adverse events) were recorded, when available. Descriptive statistics, such as frequency counts, medians, and ranges, were used to characterize the pooled sample. Nine case reports of TLS in CRC were identified in the literature; one additional case was added from our patient database. The median age of these patients was 58.5 years (range: 42-82 years) with 70% of these patients being male. Of note, 100% of these patients had metastatic colon cancer and 80% had metastatic involvement of the liver; 70% of these cases were associated with therapy-induced TLS with the median time-to-event being three days (range: 18 hours-30 days) after receiving chemotherapy. When looking at laboratory parameters, uric acid and lactate dehydrogenase (LDH) were consistently elevated in all the cases, but 50% of the cases had hyperkalemia and 50% had hyperphosphatemia. Treatment of TLS included supportive measures with IV hydration. Five out of 10 patients received urate oxidase and only one underwent hemodialysis. The overall mortality was 60%. TLS can occur with CRCs that demonstrate a high tumor burden. While most cases are associated with therapy, some cases are spontaneous in nature. Keeping in mind the high mortality associated with TLS, physicians should have a high degree of suspicion and should be aware of the fatal complications associated with TLS. Timely implementation of prophylactic and therapeutic measures including IV hydration as well as the use of xanthine oxidase inhibitors such as allopurinol can be life-saving in these cases.
Keywords: colorectal cancer; spontaneous tls (stls); tumor lysis in solid tumors; tumor lysis syndrome.
Copyright © 2020, Ansari et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.Cancer Chemother Pharmacol. 2003 Mar;51(3):187-92. doi: 10.1007/s00280-002-0556-x. Epub 2003 Feb 28. Cancer Chemother Pharmacol. 2003. PMID: 12655435
-
Intricate Interplay of Entwined Metabolic and Inflammatory Life-threatening Processes in Tumor Lysis Syndrome Complicating Prostate Cancer: A Systematic Review with a Single Institution Experience.Cureus. 2020 Mar 24;12(3):e7395. doi: 10.7759/cureus.7395. Cureus. 2020. PMID: 32226700 Free PMC article. Review.
-
Spontaneous Tumor Lysis Syndrome Secondary to Metastatic Small Cell Lung Cancer.Cureus. 2023 Feb 2;15(2):e34557. doi: 10.7759/cureus.34557. eCollection 2023 Feb. Cureus. 2023. PMID: 36879689 Free PMC article.
-
Association of Tumor Lysis Syndrome and Metastatic Melanoma.Cureus. 2021 Sep 19;13(9):e18108. doi: 10.7759/cureus.18108. eCollection 2021 Sep. Cureus. 2021. PMID: 34692319 Free PMC article.
-
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.Onco Targets Ther. 2017 Feb 2;10:597-605. doi: 10.2147/OTT.S103864. eCollection 2017. Onco Targets Ther. 2017. PMID: 28203093 Free PMC article. Review.
Cited by
-
Tumor Lysis Syndrome in a Patient with BRAFV600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib.Intern Med. 2025 Jan 1;64(1):89-93. doi: 10.2169/internalmedicine.2925-23. Epub 2024 Apr 16. Intern Med. 2025. PMID: 38631859 Free PMC article.
-
Management of acute kidney injury in gastrointestinal tumor: An overview.World J Clin Cases. 2021 Dec 16;9(35):10746-10764. doi: 10.12998/wjcc.v9.i35.10746. World J Clin Cases. 2021. PMID: 35047588 Free PMC article. Review.
-
Tumor Lysis Syndrome After mFOLFOX6 Administration for Ascending Colon Cancer.Cureus. 2025 May 27;17(5):e84896. doi: 10.7759/cureus.84896. eCollection 2025 May. Cureus. 2025. PMID: 40575200 Free PMC article.
-
Tumor Lysis Syndrome: Introduction of a Cutaneous Variant and a New Classification System.Cureus. 2021 Mar 11;13(3):e13816. doi: 10.7759/cureus.13816. Cureus. 2021. PMID: 33859885 Free PMC article. Review.
-
Infection Masquerading As Spontaneous Tumor Lysis Syndrome.Cureus. 2023 Jun 16;15(6):e40503. doi: 10.7759/cureus.40503. eCollection 2023 Jun. Cureus. 2023. PMID: 37461769 Free PMC article.
References
-
- Spontaneous tumor lysis syndrome in solid tumors: really a rare condition? Vaisban E, Braester A, Mosenzon O, Kolin M, Horn Y. Am J Med Sci. 2003;325:38–40. - PubMed
-
- Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11) Boisseau Boisseau, Bugat R, Mahjoubi M. Eur J Cancer. 1996;32A:737–738. - PubMed
-
- Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. Krishann G, D’Silva K, Al-Janadi A. J Clin Oncol. 2008;26:2406–2408. - PubMed
Publication types
LinkOut - more resources
Full Text Sources